Prevention and treatment of glucocorticoid-induced osteoporosis

被引：23

作者：

Curtis J.R. ^{[1
]}

Saag K.G. ^{[1
]}

机构：

[1] University of Alabama al Birmingham, FOT 840, Birmingham, AL 35294

来源：

Current Osteoporosis Reports | 2007年 / 5卷 / 1期

关键词：

Bone Mineral Density; Osteoporosis; Glucocorticoid; Alendronate; Ibandronate;

D O I：

10.1007/BF02938618

中图分类号：

学科分类号：

摘要：

Glucocorticoids continue to be used for many inflammatory diseases, and glucocorticoid-induced osteoporosis (GIOP) remains the most common secondary form of metabolic bone disease. Recent meta-analyses suggest that both active and native vitamin D can help maintain lumbar spine bone mineral density (BMD), particularly in patients receiving lower-dose glucocorticoid therapy. Recent randomized, controlled clinical trials have shown that oral bisphosphonates are superior to vitamin D in maintaining BMD and should be continued for as long as a person receives glucocorticoid treatment. Similar to the oral bisphosphonates, intravenous ibandronate has been shown to preserve BMD and also to significantly reduce vertebral fracture risk. Increasing evidence supports a role for parathyroid hormone to prevent or treat GIOP as well. Despite effective therapies, many at-risk patients fail to receive treatment for GIOP, and even among those who initiate treatment, half discontinue within 1 to 2 years. New approaches to evidence implementation are being tested to improve the quality of osteoporosis care and decrease fracture risk among long-term glucocorticoid users. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：14 / 21

页数：7

共 74 条

[1]

Kirwan J.R., Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis, N Engl J Med, 333, pp. 142-146, (1995)

[2]

van Everdingen A.A., Jacobs J.W.G., van Reesema D.R., Bijlsma J.W.J., Low dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease modifying properties and side effects. A double-blind placebo-controlled clinical trial, Ann Intern Med, 136, pp. 1-12, (2002)

[3]

Bijlsma J.W., Hoes J.N., van Everdingen A.A., Et al., Are glucocorticoids DMARDs?, Ann N Y Acad Sci, 1069, pp. 268-274, (2006)

[4]

Saag K.G., Koehnke R., Caldwell J.R., Et al., Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events, Am J Med, 96, pp. 115-123, (1994)

[5]

Curtis J.R., Westfall A.O., Allison J., Et al., Population-based assessment of adverse events associated with long-term glucocorticoid use, Arthritis Rheum, 55, pp. 420-426, (2006)

[6]

van Staa T.P., Geusens P., Bijlsma J.W., Et al., Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis, Arthritis Rheum, 54, pp. 3104-3112, (2006)

[7]

van Staa T., Leufkens H., Abenhaim L., Et al., Use of oral corticosteroids and risk of fractures, J Bone Miner Res, 15, pp. 993-1000, (2000)

[8]

Da Silva J.A., Jacobs J.W., Kirwan J.R., Et al., Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data, Ann Rheum Dis, 65, pp. 285-293, (2006)

[9]

Adachi J.D., Olszynski W.P., Hanley D.A., Et al., Management of corticosteroid-induced osteoporosis [review], Semin Arthritis Rheum, 29, pp. 228-251, (2000)

[10]

Adler R., Hochberg M.C., Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs, Arch Intern Med, 163, pp. 2619-2624, (2003)

← 1 2 3 4 5 6 7 8 →